Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 576 participants.

Also called NCT03658031

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 576 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03658031
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Qatar (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03658031. Randomized; no masking; primary purpose treatment. Start 2019-03-01 (anticipated); primary completion 2020-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
Condition
PreDiabetes
Condition
T2DM (Type 2 Diabetes Mellitus)
Condition
CVD
Intervention (Drug)
Dapagliflozin 10mg
Lead sponsor
Hamad Medical Corporation (class: industry)

Record details

Record id
cardio:ct-nct03658031
Content hash
6515e5ed8e4c3624bca0a908962785b5c172b3e2df8c43fcd007c6375d2f4a85